Completed as well as undergoing clinical studies are meant to assess the safety and efficacy of ipilimumab and other anti-CTLA4 antibodies as first-line treatments in advanced SCLC and NSCLC in combination with chemotherapy or other ICIs (Supplementary Table S2). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.